FI20002215A0 - Yhdistelmäpartikkelit - Google Patents

Yhdistelmäpartikkelit

Info

Publication number
FI20002215A0
FI20002215A0 FI20002215A FI20002215A FI20002215A0 FI 20002215 A0 FI20002215 A0 FI 20002215A0 FI 20002215 A FI20002215 A FI 20002215A FI 20002215 A FI20002215 A FI 20002215A FI 20002215 A0 FI20002215 A0 FI 20002215A0
Authority
FI
Finland
Prior art keywords
combination
particles
inhalation
combination particles
bronchodilator
Prior art date
Application number
FI20002215A
Other languages
English (en)
Swedish (sv)
Inventor
Esko Kauppinen
Petri Ahonen
David Brown
Esa Muttonen
Wiwik Watanabe
Original Assignee
Orion Yhtymae Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8559251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20002215(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Yhtymae Oyj filed Critical Orion Yhtymae Oyj
Priority to FI20002215A priority Critical patent/FI20002215A0/fi
Publication of FI20002215A0 publication Critical patent/FI20002215A0/fi
Priority to AT01974367T priority patent/ATE284680T1/de
Priority to CA002424620A priority patent/CA2424620A1/en
Priority to AU2001293899A priority patent/AU2001293899A1/en
Priority to JP2002532202A priority patent/JP4316873B2/ja
Priority to PCT/FI2001/000863 priority patent/WO2002028377A1/en
Priority to US10/398,373 priority patent/US7267813B2/en
Priority to DE60107862T priority patent/DE60107862T2/de
Priority to EP01974367A priority patent/EP1322300B1/en
Priority to US11/806,206 priority patent/US20080254127A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
FI20002215A 2000-10-06 2000-10-06 Yhdistelmäpartikkelit FI20002215A0 (fi)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FI20002215A FI20002215A0 (fi) 2000-10-06 2000-10-06 Yhdistelmäpartikkelit
EP01974367A EP1322300B1 (en) 2000-10-06 2001-10-05 Inhalation particles incorporating a combination of two or more active ingredients
DE60107862T DE60107862T2 (de) 2000-10-06 2001-10-05 Inhalationspartikel bestehend aus mindestens zwei wirkstoffen
AU2001293899A AU2001293899A1 (en) 2000-10-06 2001-10-05 Ihnalation particles incorporating a combination of two or more active ingredients
CA002424620A CA2424620A1 (en) 2000-10-06 2001-10-05 Inhalation particles incorporating a combination of two or more active ingredients
AT01974367T ATE284680T1 (de) 2000-10-06 2001-10-05 Inhalationspartikel bestehend aus mindestens zwei wirkstoffen
JP2002532202A JP4316873B2 (ja) 2000-10-06 2001-10-05 ２つ以上の活性成分の組合せを組み込んだ吸入粒子
PCT/FI2001/000863 WO2002028377A1 (en) 2000-10-06 2001-10-05 Ihnalation particles incorporating a combination of two or more active ingredients
US10/398,373 US7267813B2 (en) 2000-10-06 2001-10-05 Inhalation particles incorporating a combination of two or more active ingredients
US11/806,206 US20080254127A1 (en) 2000-10-06 2007-05-30 Inhalation particles incorporating a combination of two or more active ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20002215A FI20002215A0 (fi) 2000-10-06 2000-10-06 Yhdistelmäpartikkelit

Publications (1)

Publication Number Publication Date
FI20002215A0 true FI20002215A0 (fi) 2000-10-06

Family

ID=8559251

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20002215A FI20002215A0 (fi) 2000-10-06 2000-10-06 Yhdistelmäpartikkelit

Country Status (9)

Country Link
US (2) US7267813B2 (fi)
EP (1) EP1322300B1 (fi)
JP (1) JP4316873B2 (fi)
AT (1) ATE284680T1 (fi)
AU (1) AU2001293899A1 (fi)
CA (1) CA2424620A1 (fi)
DE (1) DE60107862T2 (fi)
FI (1) FI20002215A0 (fi)
WO (1) WO2002028377A1 (fi)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20011386A0 (fi) * 2001-06-28 2001-06-28 Orion Corp Inhalaatiopartikkeleja
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
ES2665464T3 (es) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CN1878602A (zh) * 2003-11-28 2006-12-13 三菱化学株式会社 有机化合物微粒的制造方法
CA2581775A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
FI20060428L (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
PT2079456E (pt) 2007-04-04 2013-03-13 Sigmoid Pharma Ltd Composições farmacêuticas de ciclosporina
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2008132707A1 (en) * 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
EP2022798A1 (en) 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
EP3552602A1 (en) * 2009-03-18 2019-10-16 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
BRPI1012196B1 (pt) 2009-05-18 2021-11-30 Sublimity Therapeutics Limited Composição compreendendo gotas de óleo
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
BR112014017481A8 (pt) * 2012-01-25 2021-06-15 Chiesi Farm Spa formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
PL3107548T3 (pl) 2014-02-20 2022-10-31 Otitopic Inc. Suche formulacje w proszku do inhalacji
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
CN107106644B (zh) 2014-11-07 2022-04-15 卓越治疗有限公司 包含环孢菌素的组合物
GB2552856A (en) * 2016-02-01 2018-02-14 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage atrial arrhythmias including atrial fibrillation
EP3768378A4 (en) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
BE1027612B1 (fr) * 2019-09-10 2021-05-03 Aquilon Pharmaceuticals Microparticules en forme de balle de golf pour une utilisation dans le traitement et la prevention de maladies pulmonaires

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
FR2624505A1 (fr) * 1987-12-11 1989-06-16 Rhone Poulenc Chimie Zircone stabilisee, son procede de preparation et son application dans des compositions ceramiques
US5096629A (en) * 1988-08-29 1992-03-17 501 Nippon Fine Chemical Co., Ltd. Method for preparing lipid powder for use in preparing liposomes and method for preparing liposomes
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DK0416950T3 (da) 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
JP3342484B2 (ja) * 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
HU226671B1 (en) * 1997-03-20 2009-06-29 Schering Corp Preparation of powder agglomerates
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
FI20002217A (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit

Also Published As

Publication number Publication date
DE60107862D1 (de) 2005-01-20
WO2002028377A1 (en) 2002-04-11
DE60107862T2 (de) 2005-12-15
ATE284680T1 (de) 2005-01-15
US7267813B2 (en) 2007-09-11
US20080254127A1 (en) 2008-10-16
US20040028619A1 (en) 2004-02-12
CA2424620A1 (en) 2002-04-11
JP4316873B2 (ja) 2009-08-19
JP2004510731A (ja) 2004-04-08
EP1322300B1 (en) 2004-12-15
AU2001293899A1 (en) 2002-04-15
EP1322300A1 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
FI20002215A0 (fi) Yhdistelmäpartikkelit
BR9915095A (pt) Composição farmacêutica ministrável em aerosol
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
MY129384A (en) "pharmaceutical formulations for dry powder inhalers in the form of hard-pellets"
FI20002216A0 (fi) Yhdistelmäpartikkelit astman hoitoon
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
BRPI0408047A (pt) medicamento contendo um agonista beta2 de longa duração altamente potente em combinação com outros princìpios ativos
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
GEP20063865B (en) Novel tiotropium-containing inhalation powder
IL219785A0 (en) Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
SE9701956D0 (sv) New composition of matter
HUP9802391A2 (hu) Inhaláló berendezés szalmeterol adagolására mért dózisban
WO2005025535A8 (en) Methods for preparing pharmaceutical compositions
TNSN05048A1 (en) Inhalation compositions with high drug ratios
SE0103211D0 (sv) New formulations and use thereof
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
WO2002015880A3 (en) Powdered mannitol and mannitol-containing compositions
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
NO20044497L (no) Torr pulver sammensetninger
AU3598299A (en) Improved compositions for inhalation
WO2005041922A3 (en) Composition
SE0103210D0 (sv) New formulations and use thereof
PL365736A1 (en) Bimodal dry powder formulation for inhalation